Xcellerant Ventures has completed its inaugural year by announcing its tenth investment, leading the Series A funding round of $10 million for CRISPR QC, a biotechnology company headquartered in San Diego. CRISPR QC has developed a pioneering platform—the first of its kind—dedicated to precisely evaluating the quality of the CRISPR/CAS9 gene editing system. This innovation aims to standardize measurements for efficiency and accuracy, enabling swift screening of potential therapeutics in pharmaceutical and agricultural sectors for the development of personalized medicines.
Dr. Chris Yoo, GP of Xcellerant Ventures, highlighted the transformative potential of CRISPR-based gene editing in addressing genetically-driven diseases. He expressed confidence in CRISPR QC becoming an essential technology for companies engaged in personalized medicine development.
Xcellerant Ventures’ role in leading the Series A investment will extend beyond funding, as the company will provide strategic guidance to CRISPR QC by joining its board. Additionally, this investment has prompted CRISPR QC to open an office in Scottsdale, tapping into Arizona’s expertise in semiconductor and medical device industries.
Ross Bundy, CEO of CRISPR QC, emphasized the synergy between the two entities, citing Xcellerant Ventures as the ideal partner for their commercialization plans. The decision to have Xcellerant lead the Series A round reflects their shared vision and strategic alignment.
Xcellerant Ventures’ track record in investing in startups that leverage technological advancements across industries resonates with their commitment to enhancing healthcare accessibility, affordability, and precision.
